Intense research is ongoing to dissect the reciprocal interactions between microbiota and drugs. New work finds that a drug to dampen host inflammation can also have off-target effects on the microbiota at transcriptional, metabolic and compositional levels, with resultant expanded benefits to the host.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Nayak, R. R. et al. Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation. Cell Host Microbe https://doi.org/10.1016/j.chom.2020.12.008 (2021).
Feagan, B. G. et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N. Engl. J. Med. 332, 292–297 (1995).
Henn, M. R. et al. A phase 1b safety study of SER-287, a spore-based microbiome therapeutic, for active mild to moderate ulcerative colitis. Gastroenterology 160, 115–127 e130 (2021).
Ervin, S. M., Ramanan, S. V. & Bhatt, A. P. Relationship between the gut microbiome and systemic chemotherapy. Dig. Dis. Sci. 65, 874–884 (2020).
Bhatt, A. P. et al. Targeted inhibition of gut bacterial beta-glucuronidase activity enhances anticancer drug efficacy. Proc. Natl Acad. Sci. USA 117, 7374–7381 (2020).
Routy, B. et al. The gut microbiota influences anticancer immunosurveillance and general health. Nat. Rev. Clin. Oncol. 15, 382–396 (2018).
Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623–628 (2018).
Kopytek, S. J., Dyer, J. C., Knapp, G. S. & Hu, J. C. Resistance to methotrexate due to AcrAB-dependent export from Escherichia coli. Antimicrob. Agents. Chemother. 44, 3210–3212 (2000).
Gibiino, G. et al. Exploring Bacteroidetes: metabolic key points and immunological tricks of our gut commensals. Dig. Liver. Dis. 50, 635–639 (2018).
Hickey, C. A. et al. Colitogenic Bacteroides thetaiotaomicron antigens access host immune cells in a sulfatase-dependent manner via outer membrane vesicles. Cell Host Microbe 17, 672–680 (2015).
A.P.B. is supported by a Career Development Award from the Crohn’s and Colitis Foundation, and the University Cancer Research Fund. R.B.S. is supported by NIH grants P01 DK094779, P30 DK034987.
A.P.B. is an inventor on United States of America Patent 16/482,998. R.B.S. receives grant support for microbial preclinical studies from Gusto Global, Vedanta, SERES Health, BiomX, Biomica and Artizan, and translational grant support from Takeda. R.B.S. is a consultant or on the Advisory Boards of Dannon/Yakult, Second Genome, SERES Health, Vedanta, Otsuka, Gusto Global, BiomX, Biomica, Takeda, Qu Biologics and Artizan.
About this article
Cite this article
Bhatt, A.P., Sartor, R.B. ‘Bugs on drugs’: implications for gut health. Nat Rev Gastroenterol Hepatol 18, 287–288 (2021). https://doi.org/10.1038/s41575-021-00437-1